U.S. market Closed. Opens in 2 hours 35 minutes

HBIO | Harvard Bioscience, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.9900 - 2.1600
52 Week Range 1.9900 - 5.56
Beta 1.36
Implied Volatility 223.73%
IV Rank 56.60%
Day's Volume 159,255
Average Volume 129,564
Shares Outstanding 43,616,600
Market Cap 94,211,856
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 2001-03-19
Valuation
Profitability
Growth
Health
P/E Ratio -6.55
Forward P/E Ratio N/A
EPS -0.33
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 391
Country USA
Website HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
HBIO's peers: INFU, PDEX, LMAT, UTMD, MLSS, POCI, KRMD, ANGO, ICUI, MMSI, AKYA
*Chart delayed
Analyzing fundamentals for HBIO we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see HBIO Fundamentals page.

Watching at HBIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HBIO Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙